Advertisement

Latest News

BPL-003 Shows Rapid Antidepressant Effect for Treatment-Resistant Depression

48 minutes ago

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

An Overview of Adalimumab Biosimilars

1 hour ago

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Screening for PsA and Selecting Right Biologic Therapy

1 hour ago

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

1 hour ago

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Choosing the Right Psoriasis Treatment: Tailoring Therapy to Patient Characteristics

1 hour ago

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Advertisement
Advertisement